Jonathan E Rosenberg

List of Publications by Year in Descending Order

202 papers	16,569 citations	53 h-index	127 g-index
217 ext. papers	21,979 ext. citations	8.1 avg, IF	6.25 L-index

#	Paper	IF	Citations
202	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.. *Journal of Clinical Oncology*, **2022**, JCO2101485	2.2	2
201	Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.. *Oncologist*, **2022**, 27, e223-e232	5.7	3
200	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.. *Cell*, **2022**, 185, 563-575.e11	56.2	11
199	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma.. *Nature Communications*, **2022**, 13, 1935	17.4	3
198	Fundamental immune-oncogenicity trade-offs define driver mutation fitness.. *Nature*, **2022**,	50.4	1
197	Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. *European Urology Focus*, **2021**, 7, 1084-1091	5.1	0
196	Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. *New England Journal of Medicine*, **2021**, 384, 1125-1135	59.2	110
195	Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. *Case Reports in Oncology*, **2021**, 14, 430-438	1	3
194	Dermatologic infections in cancer patients treated with checkpoint inhibitors. *Journal of the American Academy of Dermatology*, **2021**, 85, 1528-1536	4.5	3
193	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncology, The*, **2021**, 22, 525-537	21.7	73
192	Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy.. *Journal of Clinical Oncology*, **2021**, 39, 4539-4539	2.2	1
191	A comprehensive Memorial Sloan Kettering Cancer Center real-world data model: Core clinical data elements.. *Journal of Clinical Oncology*, **2021**, 39, e18755-e18755	2.2	0
190	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. *Genome Medicine*, **2021**, 13, 96	14.4	8
189	Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma. *Expert Opinion on Biological Therapy*, **2021**, 21, 863-873	5.4	1
188	Large cell neuroendocrine carcinoma of the urothelial tract (LNEC): The MSKCC experience.. *Journal of Clinical Oncology*, **2021**, 39, 4526-4526	2.2	0
187	Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): A multicenter, single-arm, phase 2 trial.. *Journal of Clinical Oncology*, **2021**, 39, 4517-4517	2.2	4
186	Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. *Clinical Genitourinary Cancer*, **2021**, 19, e178-e183	3.3	1

185	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. *Advances in Anatomic Pathology*, **2021**, 28, 196-208	5.1	2
184	Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. *Lancet Oncology, The*, **2021**, 22, 872-882	21.7	25
183	Developing Precision Medicine for Bladder Cancer. *Hematology/Oncology Clinics of North America*, **2021**, 35, 633-653	3.1	1
182	Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors. *Journal of Immunotherapy*, **2021**, 44, 248-253	5	2
181	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer **2021**, 9,		2
180	The biology and rationale of targeting nectin-4 in urothelial carcinoma. *Nature Reviews Urology*, **2021**, 18, 93-103	5.5	26
179	Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer. *Clinical Cancer Research*, **2021**, 27, 1997-2010	12.9	2
178	Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.016. *European Urology*, **2021**, 79, e56-e57	10.2	
177	Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer. *Clinical Cancer Research*, **2021**, 27, 2011-2022	12.9	6
176	Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma. *Journal of Urology*, **2021**, 205, 414-419	2.5	1
175	EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.. *Journal of Clinical Oncology*, **2021**, 39, 394-394	2.2	8
174	Heterogeneity and Molecular Diversity in Bladder Cancers: Deconstructing the Activity of An Antibody-Drug Conjugate. *Clinical Cancer Research*, **2021**, 27, 4950-4952	12.9	0
173	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. *Science Translational Medicine*, **2021**, 13,	17.5	14
172	Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). *Journal of Clinical Oncology*, **2021**, 39, 2486-2496	2.2	10
171	() Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract.. *Bladder Cancer*, **2021**, 7, 395-400	1	1
170	Beyond Chemotherapy and Checkpoint Inhibitors: Weighing the Risks and Benefits of the Novel Therapies for Metastatic Urothelial Carcinoma. *Journal of Clinical Oncology*, **2021**, 39, 3411-3412	2.2	1
169	Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. *British Journal of Cancer*, **2021**, 124, 1214-1221	8.7	4
168	A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract. *Cancer Medicine*, **2021**, 10, 1074-1083	4.8	3

167	High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. *Nature Medicine*, **2020**, 26, 693-698	50.5	104
166	Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 12288-12294	11.5	26
165	The emerging role of antibody-drug conjugates in urothelial carcinoma. *Expert Review of Anticancer Therapy*, **2020**, 20, 551-561	3.5	9
164	Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. *Cancer*, **2020**, 126, 2597-2606	6.4	24
163	EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. *Journal of Clinical Oncology*, **2020**, 38, 1041-1049	2.2	77
162	Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience. *Clinical Genitourinary Cancer*, **2020**, 18, 387-394	3.3	14
161	Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. *Nature Communications*, **2020**, 11, 1975	17.4	17
160	Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.. *Journal of Clinical Oncology*, **2020**, 38, 441-441	2.2	47
159	Reply by Authors. *Journal of Urology*, **2020**, 204, 684	2.5	
158	Reply by Authors. *Journal of Urology*, **2020**, 204, 259	2.5	
157	Antibody-Drug Conjugates in Urothelial Carcinomas. *Current Oncology Reports*, **2020**, 22, 13	6.3	10
156	Utility of Routine Preoperative F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy. *Journal of Urology*, **2020**, 204, 254-259	2.5	13
155	Trends in Management and Outcomes among Patients with Urothelial Carcinoma Undergoing Radical Cystectomy from 1995 to 2015: The Memorial Sloan Kettering Experience. *Journal of Urology*, **2020**, 204, 677-684	2.5	9
154	Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. *Journal of Urology*, **2020**, 204, 1173-1179	2.5	20
153	Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. *JAMA Oncology*, **2020**, 6, 84-91	13.4	33
152	Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. *Journal of Clinical Oncology*, **2020**, 38, 406-414	2.2	31
151	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees. *European Urology*, **2020**, 77, 223-250	10.2	60
150	Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma. *European Urology*, **2020**, 78, 916-924	10.2	6

149	A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma. *Cancer*, **2020**, 126, 4532-4544	6.4	2
148	Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. *European Urology*, **2020**, 78, 907-915	10.2	9
147	Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. *European Urology Oncology*, **2020**, 3, 671-679	6.7	7
146	Treatment Outcomes of Immune-Related Cutaneous Adverse Events. *Journal of Clinical Oncology*, **2019**, 37, 2746-2758	2.2	84
145	Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. *Cancer*, **2019**, 125, 3155-3163	6.4	15
144	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. *Journal of Clinical Oncology*, **2019**, 37, 1608-1616	2.2	108
143	Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. *Clinical Cancer Research*, **2019**, 25, 977-988	12.9	57
142	Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. *Journal of Clinical Oncology*, **2019**, 37, 2592-2600	2.2	226
141	Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. *JAMA Oncology*, **2019**, 5, 1790-1798	13.4	5
140	EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer.. *Journal of Clinical Oncology*, **2019**, 37, TPS4593-TPS4593	2.2	7
139	EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.. *Journal of Clinical Oncology*, **2019**, 37, 4505-4505	2.2	32
138	Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC).. *Journal of Clinical Oncology*, **2019**, 37, 377-377	2.2	14
137	MCL1 and DEDD Promote Urothelial Carcinoma Progression. *Molecular Cancer Research*, **2019**, 17, 1294-1304	6.3	2
136	Lessons learned from exceptional responders. *Expert Review of Precision Medicine and Drug Development*, **2019**, 4, 73-80	1.6	
135	Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. *European Urology Oncology*, **2019**, 2, 248-256	6.7	9
134	PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies. *American Journal of Surgical Pathology*, **2019**, 43, 920-927	6.7	30
133	The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. *Oncologist*, **2019**, 24, 1348-1355	5.7	7
132	Refining existing knowledge and management of bladder cancer. *Nature Reviews Urology*, **2019**, 16, 75-76	5.5	1

131	Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. *Cancer*, **2019**, 125, 533-540	6.4	26
130	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. *Nature Genetics*, **2019**, 51, 202-206	36.3	1435
129	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. *Clinical Cancer Research*, **2019**, 25, 967-976	12.9	94
128	SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. *World Journal of Urology*, **2019**, 37, 95-105	4	12
127	Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. *European Urology*, **2019**, 75, 231-239	10.2	53
126	The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer. *European Urology*, **2019**, 75, 435-444	10.2	54
125	Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. *European Urology Focus*, **2019**, 5, 201-204	5.1	18
124	Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes. *Cell Reports*, **2018**, 23, 512-521	10.6	43
123	Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma. *Urologic Clinics of North America*, **2018**, 45, 287-295	2.9	8
122	TGF attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. *Nature* , **2018**, 554, 544-548	50.4	1697
121	Nivolumab for the treatment of urothelial cancers. *Expert Review of Anticancer Therapy*, **2018**, 18, 215-222	3.5	14
120	Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. *European Urology*, **2018**, 73, 462-468	10.2	23
119	Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. *Clinical Genitourinary Cancer*, **2018**, 16, e961-e967	3.3	12
118	Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. *Human Pathology*, **2018**, 77, 63-69	3.7	18
117	Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. *Clinical Genitourinary Cancer*, **2018**, 16, e483-e490	3.3	8
116	Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. *Acta Oncologica*, **2018**, 57, 491-497	3.2	14
115	EMA and FDA prune the checkpoint inhibitor treatment landscape. *Nature Reviews Urology*, **2018**, 15, 596-597	5.5	5
114	Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210.. *Journal of Clinical Oncology*, **2018**, 36, 4523-4523	2.2	23

113	EV-103 study: A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer.. *Journal of Clinical Oncology*, **2018**, 36, TPS532-TPS532	2.2	4
112	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. *Clinical Cancer Research*, **2018**, 24, 1965-1973	12.9	51
111	Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. *Journal of Clinical Oncology*, **2018**, 36, 1685-1694	2.2	274
110	Reply to S. Zhang et al. *Journal of Clinical Oncology*, **2018**, 36, 3057-3058	2.2	
109	Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. *Journal of Clinical Oncology*, **2018**, 36, 1949-1956	2.2	72
108	SnapShot: Bladder Cancer. *Cancer Cell*, **2018**, 34, 350-350.e1	24.3	18
107	A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor. *PLoS ONE*, **2018**, 13, e0208422	3.7	10
106	Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. *British Journal of Cancer*, **2018**, 119, 707-712	8.7	18
105	Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. *Journal of Urology*, **2018**, 200, 1207-1214	2.5	10
104	Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). *British Journal of Cancer*, **2018**, 118, 1434-1441	8.7	17
103	Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with Alterations. *Cancer Discovery*, **2018**, 8, 812-821	24.4	145
102	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. *Clinical Cancer Research*, **2017**, 23, 3610-3618	12.9	143
101	Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. *Cancer Medicine*, **2017**, 6, 186-194	4.8	10
100	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. *Lancet, The*, **2017**, 389, 67-76	40	1171
99	Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). *European Urology*, **2017**, 71, 281-289	10.2	41
98	Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. *PLoS Medicine*, **2017**, 14, e1002309	11.6	170
97	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma **2017**, 5, 68		48
96	Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. *European Urology*, **2017**, 72, 952-959	10.2	168

95	Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma of the Bladder who failed Bacillus Calmette Guerin (NCT01259063). *Bladder Cancer*, **2017**, 3, 113-119	1	8
94	Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. *Journal of Oncology Practice*, **2017**, 13, 621-625	3.1	27
93	Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer. *Clinical Genitourinary Cancer*, **2017** ,	3.3	7
92	Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. *Clinical Genitourinary Cancer*, **2017**,	3.3	2
91	The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy. *Clinical and Applied Thrombosis/Hemostasis*, **2017**, 23, 755-760	3.3	13
90	Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. *Nature Reviews Clinical Oncology*, **2017**, 14, 221-234	19.4	66
89	Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. *Journal of Clinical Oncology*, **2017**, 35, 709-717	2.2	587
88	Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. *Nature Communications*, **2017**, 8, 2193	17.4	62
87	A phase I study of enfortumab vedotin (ASG-22CE; ASG-22ME): Updated analysis of patients with metastatic urothelial cancer.. *Journal of Clinical Oncology*, **2017**, 35, 106-106	2.2	19
86	DNA damage repair and response (DDR) gene alterations (alt) and response to PD1/PDL1 blockade in platinum-treated metastatic urothelial carcinoma (mUC).. *Journal of Clinical Oncology*, **2017**, 35, 4509-4509	2.2	12
85	Cancer predisposing germline mutations in patients (pts) with urothelial cancer (UC) of the renal pelvis (R-P), ureter (U) and bladder (B).. *Journal of Clinical Oncology*, **2017**, 35, 4510-4510	2.2	9
84	Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma. *Bladder Cancer*, **2016**, 2, 111-117	1	4
83	Clonal evolution of chemotherapy-resistant urothelial carcinoma. *Nature Genetics*, **2016**, 48, 1490-1499	36.3	161
82	Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. *Scientific Reports*, **2016**, 6, 27702	4.9	38
81	Circulating biomarkers to guide systemic therapy for urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 502-509	2.8	6
80	Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. *Bladder Cancer*, **2016**, 2, 165-202	1	22
79	The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents. *Cancer*, **2016**, 122, 712-21	6.4	23
78	Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma. *Clinical Genitourinary Cancer*, **2016**, 14, e81-90	3.3	4

77	Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. *JAMA Oncology*, **2016**, 2, 1094-6	13.4	134
76	Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?. *European Journal of Cancer*, **2016**, 53, 96-104	7.5	21
75	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. *Nature Genetics*, **2016**, 48, 356-8	36.3	111
74	Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. *Journal of Urology*, **2016**, 195, 1684-1689	2.5	27
73	Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. *Clinical Genitourinary Cancer*, **2016**, 14, 352-9	3.3	21
72	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. *Lancet, The*, **2016**, 387, 1909-20	40	2308
71	Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. *Journal of Urology*, **2016**, 195, 277-82	2.5	40
70	Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank. *Bladder Cancer*, **2016**, 2, 203-213	1	2
69	A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. *Cancer*, **2016**, 122, 2389-98	6.4	9
68	Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. *Nature Genetics*, **2016**, 48, 600-606	36.3	238
67	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. *Lancet Oncology, The*, **2016**, 17, 1590-1598	21.7	450
66	Genomic characterization of response to chemoradiation in urothelial bladder cancer. *Cancer*, **2016**, 122, 3715-3723	6.4	37
65	The role of genomics in the management of advanced bladder cancer. *Current Treatment Options in Oncology*, **2015**, 16, 319	5.4	10
64	The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience. *Oncologist*, **2015**, 20, 508-15	5.7	34
63	Re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014. *European Urology*, **2015**, 68, e31-2	10.2	3
62	First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients. *Hematology/Oncology Clinics of North America*, **2015**, 29, 319-28, ix-x	3.1	19
61	Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 53-64	2.8	11
60	DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. *BMC Cancer*, **2015**, 15, 242	4.8	20

59	Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma. *Clinical Genitourinary Cancer*, **2015**, 13, 410-20	3.3	16
58	Novel molecular targets for urothelial carcinoma. *Expert Opinion on Therapeutic Targets*, **2015**, 19, 515-25	3.4	6
57	Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. *Cancer*, **2015**, 121, 2586-93	6.4	120
56	Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. *Clinical Genitourinary Cancer*, **2015**, 13, 250-6	3.3	5
55	Genomic Characterization of Upper Tract Urothelial Carcinoma. *European Urology*, **2015**, 68, 970-7	10.2	147
54	HER2 as a target in invasive urothelial carcinoma. *Cancer Medicine*, **2015**, 4, 844-52	4.8	31
53	Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. *Cancer*, **2015**, 121, 2603-11	6.4	9
52	Treatment Decision Making in Patients with Bladder Cancer. *Bladder Cancer*, **2015**, 1, 151-158	1	16
51	Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. *European Urology*, **2015**, 67, 198-201	10.2	105
50	Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. *Clinical Genitourinary Cancer*, **2015**, 13, 185-92	3.3	2
49	Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors. *PLoS ONE*, **2015**, 10, e0124711	3.7	15
48	A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. *Investigational New Drugs*, **2014**, 32, 178-87	4.3	226
47	Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. *European Journal of Cancer*, **2014**, 50, 3145-52	7.5	82
46	Optimal treatment for metastatic bladder cancer. *Current Oncology Reports*, **2014**, 16, 404	6.3	30
45	Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. *Cancer Discovery*, **2014**, 4, 546-53	24.4	224
44	Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. *Journal of Clinical Oncology*, **2014**, 32, 1889-94	2.2	177
43	Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. *Clinical Genitourinary Cancer*, **2014**, 12, 130-7	3.3	26
42	Identification of ALK gene alterations in urothelial carcinoma. *PLoS ONE*, **2014**, 9, e103325	3.7	8

41	Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. *Cancer Discovery*, **2014**, 4, 1140-53	24.4	361
40	Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. *Clinical Cancer Research*, **2014**, 20, 1873-83	12.9	38
39	Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. *Journal of Clinical Oncology*, **2014**, 32, 4171-2	2.2	
38	FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. *Cancer Medicine*, **2014**, 3, 835-44	4.8	63
37	Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. *Cancer Discovery*, **2014**, 4, 1014-21	24.4	98
36	Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. *International Journal of Radiation Oncology Biology Physics*, **2014**, 88, 1048-56	4	57
35	The evolving understanding of microRNA in bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 41.e31-40	2.8	57
34	Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma.. *Journal of Clinical Oncology*, **2014**, 32, 4510-4510	2.2	2
33	Efficacy of single-agent pemetrexed in platinum refractory metastatic urothelial cancer (mUC).. *Journal of Clinical Oncology*, **2014**, 32, 322-322	2.2	2
32	Gemcitabine-cisplatin (GC) plus radical cystectomy-pelvic lymph node dissection (RC-PLND) for patients (pts) with muscle-invasive bladder cancer (MIBC): Assessing impacts of neoadjuvant chemotherapy (NAC) and the PLND.. *Journal of Clinical Oncology*, **2014**, 32, 355-355	2.2	7
31	Molecular targets on the horizon for kidney and urothelial cancer. *Nature Reviews Clinical Oncology*, **2013**, 10, 557-70	19.4	18
30	Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. *Journal of Clinical Oncology*, **2013**, 31, 181-6	2.2	336
29	Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. *Critical Reviews in Oncology/Hematology*, **2013**, 87, 80-9	7	49
28	Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. *European Urology*, **2013**, 63, 717-23	10.2	88
27	Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. *Cancer*, **2013**, 119, 1994-8	6.4	10
26	Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value. *PLoS ONE*, **2013**, 8, e60927	3.7	24
25	Actionable mutations in muscle-invasive bladder cancer. *Current Opinion in Urology*, **2013**, 23, 472-8	2.8	15
24	The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. *Clinical Cancer Research*, **2013**, 19, 5218-26	12.9	65

23	Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. *Journal of the National Cancer Institute*, **2013**, 105, 499-503	9.7	63
22	Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches. *Frontiers in Pharmacology*, **2013**, 4, 3	5.6	18
21	Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. *Clinical Cancer Research*, **2012**, 18, 1323-33	12.9	138
20	Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer. *Clinical Genitourinary Cancer*, **2012**, 10, 21-5	3.3	5
19	Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. *Journal of Clinical Oncology*, **2012**, 30, 507-12	2.2	151
18	Correlation of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in an analysis of 10 trials of second-line therapy for advanced urothelial carcinoma (UC).. *Journal of Clinical Oncology*, **2012**, 30, 4525-4525	2.2	1
17	FGFR3 protein expression and gene mutation in primary and metastatic urothelial carcinoma (UC) tumors.. *Journal of Clinical Oncology*, **2012**, 30, 4577-4577	2.2	1
16	PI3KCA mutations in advanced urothelial carcinoma: A potential therapeutic target?. *Journal of Clinical Oncology*, **2012**, 30, 4582-4582	2.2	
15	Impact of first-line platinum therapy on survival in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium (TCCU) treated with vinflunine.. *Journal of Clinical Oncology*, **2012**, 30, e15007-e15007	2.2	
14	External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy.. *Journal of Clinical Oncology*, **2012**, 30, 4592-4592	2.2	
13	Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices. *Hematology/Oncology Clinics of North America*, **2011**, 25, 893-915	3.1	19
12	A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. *Lancet Oncology, The*, **2011**, 12, 211-4	21.7	186
11	Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. *Journal of Clinical Oncology*, **2011**, 29, 2432-8	2.2	349
10	Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. *Journal of Clinical Oncology*, **2010**, 28, 2280-5	2.2	346
9	Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. *Journal of Clinical Oncology*, **2010**, 28, 1850-5	2.2	268
8	Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma. *Journal of Clinical Oncology*, **2010**, 28, e205-7; author reply e208	2.2	8
7	Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. *Lancet Oncology, The*, **2010**, 11, 861-70	21.7	105
6	Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. *Journal of Clinical Oncology*, **2009**, 27, 2772-8	2.2	30

5	Bladder cancer: modeling and translation. *Genes and Development*, **2009**, 23, 655-9	12.6	10
4	Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. *Journal of Clinical Oncology*, **2008**, 26, 3743-8	2.2	346
3	What is the current status of second-line chemotherapy for castration-resistant prostate cancer?. *Nature Reviews Urology*, **2008**, 5, 650-1		1
2	A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. *Cancer*, **2005**, 103, 2035-41	6.4	43
1	Molecular events in muscle-invasive bladder cancer development327-341		